PMID- 10570446
OWN - NLM
STAT- MEDLINE
DCOM- 20000104
LR  - 20131121
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 86
IP  - 10
DP  - 1999 Nov 15
TI  - Octreotide improves biochemical, radiologic, and symptomatic indices of 
      gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia 
      type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
PG  - 2154-9
AB  - BACKGROUND: Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant 
      tumor syndrome associated with parathyroid, gastroenteropancreatic (GEP), and 
      pituitary neoplasia. Gastrinoma and GEP malignancy are common life-threatening 
      endocrine complications of MEN-1. An effective management strategy for these 
      disorders remains to be determined. The authors attempted to determine the role 
      of the somatostatin analogue, octreotide, in ameliorating features of 
      hypergastrinemic GEP neoplasia associated with MEN-1. METHODS: Five MEN-1 
      patients with hypergastrinemia and either symptoms of GEP neoplasia or hepatic 
      metastases received a trial of octreotide, 100 microg subcutaneously, three times 
      daily for 3 months. RESULTS: Treatment with octreotide was associated with a 
      rapid symptomatic and biochemical response. In all patients serum gastrin fell to 
      < 25% of the pretreatment value. The serum glycoprotein-alphasubunit (a marker of 
      enterochromaffin-like [ECL] cell hyperplasia, gastric carcinoidosis, and 
      disseminated enteropancreatic malignancy) was elevated at baseline in three 
      patients. In each case the serum glycoprotein-alphasubunit normalized after 
      treatment with octreotide. Hepatic metastases were present in two patients at 
      baseline. The size of the metastases diminished by up to 15% during the period of 
      octreotide treatment. Four patients reported symptoms prior to treatment: 
      lethargy, easy fatigability, and generalized musculoskeletal discomfort. A marked 
      symptomatic improvement occurred in each case. No patient experienced side 
      effects related to octreotide therapy and all elected to remain on treatment 
      after completion of the trial. CONCLUSIONS: Octreotide is a safe and effective 
      adjunct to surgical strategies for the management of GEP neoplasia in 
      hypergastrinemic MEN-1 patients.
CI  - Copyright 1999 American Cancer Society.
FAU - Burgess, J R
AU  - Burgess JR
AD  - Department of Diabetes, Royal Hobart Hospital, Hobart, Tasmania, Australia.
FAU - Greenaway, T M
AU  - Greenaway TM
FAU - Parameswaran, V
AU  - Parameswaran V
FAU - Shepherd, J J
AU  - Shepherd JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Gastrins)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Female
MH  - Gastrins/blood
MH  - Gastrointestinal Neoplasms/*drug therapy
MH  - Humans
MH  - Middle Aged
MH  - *Models, Biological
MH  - Multiple Endocrine Neoplasia Type 1/*drug therapy
MH  - Octreotide/*therapeutic use
MH  - Pancreatic Neoplasms/*drug therapy
EDAT- 1999/11/26 00:00
MHDA- 1999/11/26 00:01
CRDT- 1999/11/26 00:00
PHST- 1999/11/26 00:00 [pubmed]
PHST- 1999/11/26 00:01 [medline]
PHST- 1999/11/26 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-W [pii]
PST - ppublish
SO  - Cancer. 1999 Nov 15;86(10):2154-9.